177 results about "Liver Cirrhoses" patented technology

The invention discloses a 4D-Flow-CFD simulation model construction method and system for quantitative evaluation of cirrhosis portal vein hydrodynamics, and belongs to the technical field of medical image processing, the construction method comprises the following steps: step 1, placing a patient on a scanner, and sequentially performing structural image and 4D-Flow MRI (four-dimensional blood flow magnetic resonance) scanning; 2, integrating the 4D-Flow MRI and CFD (computational fluid dynamics) technology, performing post-processing on a 4D-Flow MRI image by adopting Circle software, and screening out hemodynamic characteristic parameters capable of representing the liver cirrhosis process; and 3, constructing a liver portal vein system finite element model by using the screened haemodynamic characteristic parameters so as to establish a quantitative evaluation model of portal vein haemodynamics of the patients with cirrhosis, so that a new haemodynamic detection method is explored for clinical systematic evaluation of cirrhosis, and a new thought is provided for accurate evaluation of cirrhosis.

The invention belongs to the technical field of preparation of sea cucumber peptides, relates to preparation of sea cucumber small molecule peptides, and relates to a preparation method of sea cucumber peptides with composite effects of protecting liver and preventing liver cirrhosis, and the sea cucumber peptides with various effects are prepared by using fresh and alive sea cucumbers as raw materials through protease hydrolysis, fishy smell removal, deodorization and other processes. The sea cucumber peptide has the advantages of good solubility, good stability, low viscosity and the like. Compared with the transportation function of amino acid, the sea cucumber active oligopeptide has the characteristics of quick absorption, low consumption and difficulty in saturation, can be added into food, health food, medicine and the like, and has the effects of supplementing nutrition, protecting the liver function, preventing liver cirrhosis, supplementing mineral substances, protein and vitamins and the like.

The invention relates to the technical field of hepatobiliary patient body data prediction, in particular to a hepatobiliary patient risk early warning method and system based on deep learning. According to the method, the lesion parameters are obtained according to the change of the body data of each dimension in a long time; obtaining a dimension influence degree according to the number of liver cancer patients and the lesion parameter distribution of the liver cirrhosis patients in each dimension; according to the similarity degree of the to-be-analyzed patient and the liver cancer patient in each dimension, the lesion similarity degree is obtained, and prediction parameters of the to-be-analyzed patient are obtained in combination with the dimension influence degree and the lesion parameters. And performing risk prediction on the to-be-analyzed patient according to the prediction parameters. According to the method, the body data of each dimension of the long-term cirrhosis patient is analyzed, and the relevance between the complexity of the judgment process and the body data of each dimension is considered, so that the risk early warning of the long-term cirrhosis patient can be accurately performed.

The invention relates to the field of biomedical application of inorganic materials, in particular to application of lanthanum carbonate in preparation of drugs for resisting liver cirrhosis and inhibiting liver inflammations, the drugs comprise lanthanum carbonate and pharmaceutically acceptable auxiliary materials, the drugs are ground and then mixed with food to prepare a drug mixture, and the drug mixture is prepared into the drug for resisting liver cirrhosis and inhibiting liver inflammations. The mass ratio of the lanthanum carbonate in the medicine mixture is 1-10%, and the mechanism of the lanthanum carbonate for treating the liver cirrhosis is as follows: interference or blocking of activation and proliferation of hepatic stellate cells, inhibition of extracellular matrix generation and promotion of extracellular matrix degradation. According to the invention, a rat liver cirrhosis model is constructed through chemical induction, and the effects of reversing liver cirrhosis and inhibiting liver inflammation are found when a rat is treated by taking lanthanum carbonate orally, so that a new candidate drug is provided for clinical treatment of liver cirrhosis.

The invention relates to the fields of biology, medicine and clinic. The invention specifically relates to application of a reagent targeting an eIF2alpha / ATF4 pathway in treatment of hepatic fibrosis diseases. Based on research of the inventor of the invention, on one hand, the invention discloses application of a reagent for targeted inhibition of an eIF2alpha / ATF4 pathway in preparation of drugs for treating hepatic fibrosis diseases, or application of the reagent in preparation of drugs for preventing liver cirrhosis and / or liver cancer; on the other hand, the invention discloses an application of the eIF2alpha / ATF4 pathway protein and / or the coding gene thereof in screening of drugs for treating hepatic fibrosis diseases, or an application in screening of drugs for preventing liver cirrhosis and / or liver cancer. Another aspect of the invention discloses a pharmaceutical composition comprising an agent for targeted inhibition of expression or activity of an eIF2alpha / ATF4 pathway protein; the invention has considerable application prospects in clinical treatment of hepatic fibrosis diseases.

The invention discloses a double-chain miRNA, a pharmaceutical composition containing the same, an anti-aging product and application of the double-chain miRNA. The double-stranded miRNA comprises a chemically modified sense strand with a sequence shown as SEQ ID NO: 1 and a chemically modified antisense strand with a sequence shown as SEQ ID NO: 2, wherein the chemical modification of the sense strand and the antisense strand each comprises a 2 '-substituted nucleotide and a modified nucleotide bond; the chemically modified nucleotide bond is at least located at one or more of the 1st-3rd and 20th-23rd sites of the sequence shown as SEQ ID NO: 1 and / or SEQ ID NO: 2. The double-chain miRNA is good in stability and has a remarkable treatment effect on skin cell photoaging, Alzheimer's disease, articular cartilage injury, diabetes, non-alcoholic fatty liver disease, androgenetic alopecia, cirrhosis and chronic nephritis. In short, the effect and the stability of the product are both considered, and the application prospect is good.

The invention discloses a traditional Chinese medicine composition for treating liver cirrhosis and a preparation method thereof, and belongs to the technical field of anti-liver cirrhosis traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 10g of polyporus umbellatus, 10g of herba artemisiae scopariae, 10g of radix bupleuri, 10g of charred rheum officinale, 10g of rhizoma coptidis, 10g of charred radix scutellariae, 10g of fructus gardeniae, 15g of herba hyperici japonici, 10g of radix curcumae, 10g of rhizoma alismatis, 10g of radix paeoniae rubra, 10g of radix salviae miltiorrhizae, 10g of cortex magnoliae officinalis, 10g of fructus aurantii, 10g of rhizoma cyperi, 10g of rhizoma sparganii, 10g of rhizoma curcumae, 20g of plantain herb, 10g of turtle shell, 10g of pericarpium arecae, 25g of oven earth and 2g of charred colla corii asini. By providing the traditional Chinese medicine composition formula for treating the liver cirrhosis, the effective rate and the cure rate of the medicine for treating the liver cirrhosis are improved.

Combinations of fatty acid synthesis (FASN) inhibitors and glucagon-like peptide-1 (GLP-1) agonists for treating NAFLD / MAFLD, NASH / MASH, liver fibrosis and / or liver cirrhosis.

The invention discloses a long-term prognosis prediction system and method for patients with liver diseases, and the method comprises the following steps: S1, collecting clinical data, including anthropometric data, vital signs, laboratory data and albumin binding capacity obtained by specific detection, of patients with acute decompensation of liver cirrhosis and chronic plus acute liver failure; s2, a competitive risk model for predicting death of patients suffering from acute decompensation of liver cirrhosis and chronic and acute hepatic failure after admission for one year is constructed, the prediction model is constructed by adopting the competitive risk model, and a convenient prediction tool is made by adopting a dynamic column diagram visual prediction model; and S3, evaluating the prediction performance of the model through the working curve of the subject. According to the present invention, the index relationship between the albumin binding capacity and the long-term prognosis of the decompensated liver cirrhosis patient and the chronic plus acute liver failure patient is established so as to provide the important clinical significance, such that the clinical management can be further optimized, and the drug treatment can be guided.

The invention relates to a liver cirrhosis prediction and noninvasive diagnosis system and method for autoimmune hepatitis, and belongs to the technical field of medicine. The system comprises a data acquisition module, a data processing module and a model construction module. The data acquisition module is used for acquiring blood detection indexes of a patient, including total protein, albumin, total bilirubin, direct bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), glutamyltranspeptidase (GGT), urea, creatinine, platelet count (PLT) and the like. The model building module is combined with blood detection data and clinical pathology data, a statistical analysis method such as binary Logistic regression is adopted, and a liver cirrhosis prediction model is trained and built. Based on four key blood detection indexes, the method can effectively predict the occurrence of liver cirrhosis of AIH patients, and especially provides a scientific reference for noninvasive diagnosis and curative effect monitoring for patients who cannot perform liver puncture or reject liver puncture.

The invention discloses a liver cirrhosis microbial marker as well as a screening method and application thereof, and solves the technical problems of few markers, small clinical queue scale and unknown effectiveness in predicting the future liver cirrhosis risk in the existing intestinal flora biomarker research. The method comprises the following steps: by integrating whole genome association research data (GWAS) and 16S rRNA gene sequencing data, screening out candidate microbial differential bacteria related to liver cirrhosis by adopting difference analysis; in combination with LDSC analysis and a double-sample Mendel randomization method, MR related bacteria and LDSC genetic related bacteria are screened from the aspects of causal correlation and genetic correlation; taking an intersection of the differential bacteria, the MR related bacteria and the LDSC genetic related bacteria as a marker; finally, model training is conducted through a machine learning algorithm by means of a data set with sample labels, individual liver cirrhosis risk prediction labels are output, early screening of liver cirrhosis is achieved, and the method can be widely applied to the technical field of intestinal microorganism and data mining.

Featured are methods of identifying (e.g., diagnosing) and / or treating a subject having or at risk of developing a liver disorder, such as liver steatosis, liver fibrosis, liver cirrhosis, and / or liver cancer (e.g., HCC). The methods utilize predictive and / or diagnostic biomarkers for identifying a subject as having or having a risk of a liver disorder. The predictive and / or diagnostic biomarkers described herein can also be used to monitor the status of a subject determined to have liver disorder or a risk thereof during treatment with a liver therapy. Also disclosed are methods of treating a subject determined to have a liver disorder (e.g., liver cancer, such as HCC) or a risk thereof (e.g., by assessing the level of one or more of the disclosed biomarkers by administering a liver therapy to the subject.

To provide a composition for improving liver health.SOLUTION: In one aspect, the composition of the present invention includes a complex component of Gallocatechin Gallate and Isoquercitrin, which effectively reduces oxidative stress and chronic inflammatory reaction that occur during the accumulation of lipids in liver tissue, thereby improving liver health and enabling the prevention, improvement, or treatment of various liver diseases such as hepatitis, cirrhosis, and liver cancer.SELECTED DRAWING: Figure 1

The invention discloses an application of a biomarker in evaluating the risk of progressing from autoimmune hepatitis to cirrhosis. The biomarker comprises immune globulin G, and / or an antinuclear antibody, and / or aspartate aminotransferase and alanine aminotransferase. Independent predictive factor indexes of the liver cirrhosis risk of an autoimmune hepatitis patient in the biomarker are as follows: an antinuclear antibody ANA index: log2ANA is greater than or equal to 1.62; the AAR index of the ratio of aspartate aminotransferase to alanine aminotransferase is as follows: AAR is greater than or equal to 1.62; the immune globulin G, namely the IgG index, is greater than or equal to 30.3 g / L. The problems that in the prior art, an AIH risk model does not take cirrhosis as the outcome, visual presentation is lacked, prediction efficiency is insufficient, and clinical early-stage accurate risk layering and diagnosis and treatment decision requirements are difficult to meet are solved.

The present application relates to the technical field of medical information processing, in particular to a liver cirrhosis prognosis risk detection system. After each detection of the patient's liver by the system, the image data can quantify the image liver cirrhosis risk from the morphological changes in the liver region. According to the difference between the actual detection data and the prediction data, and the prognosis response non-normality, the disease progression index is determined. The drug adjustment data is used to determine the drug adjustment degree, and then the liver cirrhosis progression index is obtained. The data lag and the liver cirrhosis progression index are quantified to adjust the detection frequency of the system. The present application enables the system to effectively respond to the patient's condition and generate an effective early warning signal to remind medical staff to perform liver detection when necessary.

The invention relates to a gulcomannan modified mesoporous dopamine targeted multifunctional nano diagnosis and treatment agent and preparation and application thereof.The targeted multifunctional nano diagnosis and treatment agent comprises a carrier and lovastatin, the carrier is a manganese ion coordinated mesoporous polydopamine carrier, and the surface of the carrier is modified with gulcomannan. The diagnosis and treatment agent has a good drug loading rate and a good delivery effect, overcomes the defect of low oral absorption rate of single lovastatin, can carry out MRI imaging monitoring, and provides a new thought for integration of diagnosis and treatment of liver cirrhosis.

Provided herein is a method of diagnosing or prognosing advanced liver fibrosis or liver cirrhosis in a patient. The method is accomplished by determining a score based on the circulating levels in serum of three markers.

The invention provides an antrodia camphorata sporocarp extract, which is prepared from the following raw materials in parts by weight: 20 to 24 parts of wild ganoderma lucidum extract, 8 to 12 parts of herba taraxaci and 8 to 12 parts of bolete. The antrodia camphorata sporocarp extract disclosed by the invention contains various physiologically active components such as triterpenoids, polysaccharides, superoxide disproportionated enzymes, adenosine, proteins (containing immune proteins), vitamins, trace elements, nucleic acid, lectin, amino acid, sterols, lignin, blood pressure stabilizing substances and the like; the traditional Chinese medicine composition can relieve various tumors such as hangover, gastrointestinal discomfort, heatstroke, hypertension, virus infection, diabetes mellitus, nephritis, liver cirrhosis and liver cancer, has the effects of resisting oxidation, resisting inflammation, inhibiting hypertension, protecting liver nerves, inhibiting tumor growth and the like, can bidirectionally regulate immunity and protect the liver, can also treat tumors at multiple targets, and has a wide application prospect. The discomfort of a patient in an anti-tumor process is reduced.

To provide terlipressin compositions and their methods of use.SOLUTION: Disclosed herein are methods for treating or preventing hypotension (e.g., neurogenic orthostatic hypotension or postprandial hypotension) or portal hypertension (e.g., bleeding esophageal varices associated with portal hypertension) or ascites (e.g., ascites associated with liver cirrhosis), by oral administration to affected subjects of compositions comprising a therapeutically effective amount of terlipressin or a pharmaceutically acceptable salt thereof. In some embodiments, terlipressin exhibits improved bioavailability (BA) in a composition or oral dosage form described herein relative to terlipressin configured in another formulation or dosage form.SELECTED DRAWING: None

The invention discloses application of indole-3-propionic acid in preparation of a medicine for preventing or treating hematogenous infection, and belongs to the technical field of biological medicine. The invention discloses the application of indole-3-propionic acid in resisting blood-borne infection for the first time, the capability of capturing blood-borne pathogenic bacteria by liver Kupu cells can be remarkably enhanced by giving indole-3-propionic acid, and the load of pathogenic bacteria in circulating blood is reduced. The invention provides a new thought for treatment of hematogenous infection, especially anti-infection treatment of susceptible people with severe hepatitis or liver cirrhosis and the like. Indole-3-propionic acid is low in price and easy to obtain, can be produced in a large scale, is favorable for being developed into a medicine for treating hematogenous infection, and has a good application value.

The invention belongs to the technical field of biotechnology, and particularly relates to application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit and a detection method. The invention provides an application of an exosome MZF1 protein marker in a liver cirrhosis diagnosis / treatment medicine or reagent, a kit for liver cirrhosis diagnosis / treatment and a detection method of a serum exosome MZF1 protein. The exosome MZF1 protein is used as a marker, a valuable reagent or drug application prospect is provided for early diagnosis and treatment of liver cirrhosis, and help is provided for analysis of more serum exosome proteins applied to liver cirrhosis markers.

The invention relates to a traditional Chinese medicine composition for treating liver diseases such as chronic hepatitis, liver cirrhosis, liver cancer and the like, a preparation method and application in preparation of medicines for treating liver diseases. The traditional Chinese medicine composition is prepared into pills or granules, powder, capsules and the like from 0.15-36 parts by weight of sliced white aconite and 0.3-6 parts by weight of ligusticum wallichii according to the conventional preparation process of Chinese patent medicines. The effective rates of the traditional Chinese medicine composition for treating chronic hepatitis, cirrhosis and liver cancer respectively reach 87%, 75% and 70% or above. The traditional Chinese medicine composition has the characteristics of simple medicine composition, prominent curative effect, low production cost, simple and mature preparation process and the like.

The present invention discloses a pharmaceutical composition for treating non-alcoholic steatohepatitis, liver fibrosis and / or liver cirrhosis, which is prepared from the following raw materials in the following weight ratios: 15-50 parts of Astragalus membranaceus, 5-25 parts of turtle shell, 5-25 parts of Angelica sinensis, 10-30 parts of safflower, 10-30 parts of peach kernel, and 1-10 parts of liquorice. The pharmaceutical composition of the present invention for treating non-alcoholic steatohepatitis can reduce serum transaminase, and significantly reduce lipid deposition, liver tissue inflammation and collagen fiber deposition; the composition of the present invention for treating liver fibrosis can significantly reduce liver tissue pathological inflammation and collagen fiber deposition, as well as the numerical values of related indexes such as serum liver function ALT and AST, and at the same time significantly down-regulate the numerical values of related indexes such as serum PⅢP, PCⅣ, HA and LN, significantly inhibit the activation of hepatic stellate cells (HSCs), the central link of liver fibrosis, significantly reduce the activation of NLRP3 inflammasome in liver tissue, reduce HSC autophagy and activation, and has a good therapeutic effect on both liver fibrosis and liver cirrhosis.

The present invention relates to the field of liver disease, and more particularly to a method for determining the presence of chronic plus acute liver failure or for determining the risk of developing ACLF in a patient suffering from cirrhosis or a delayed early stage of ACLF. The invention also relates to a method for distinguishing patients suffering from decompensated liver cirrhosis, acute decompensated liver cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, a method for determining the degree of systemic inflammation and a method for determining the presence of a bacterial infection with sepsis.

In the present specification, disclosed is a method for preparing a gallocatechin gallate (Gallocatable Gallate), which comprises the steps of: preparing a gallocatechin gallate (Gallocatable Gallate; the present invention relates to uses of a composition for enhancing liver health or for auxiliary protection against chemical liver injury, in particular to uses of a composition for enhancing liver health or for auxiliary protection against chemical liver injury, such as GCG, isoquercitrin, IQC, and to the preparation of a composition for enhancing liver health or for auxiliary protection against chemical liver injury. In one aspect, the composition of the present invention can include a composite component of gallocatechin gallate and isoquercitrin to effectively reduce oxidative stress and chronic inflammatory response occurring in the process of lipid accumulation in liver tissue to improve liver health, and is applied to prevention, improvement or treatment of various liver diseases such as hepatitis, cirrhosis, liver cancer and the like.

The invention discloses an application of an epoxidase type II inhibitor, the application is the application in preparation of drugs for treating liver injury, hepatitis, hepatic fibrosis, or liver function decline or complications thereof, and the application discovers that the existing COX-2 selective inhibitors such as celecoxib and the like and a novel efficient COX-2 selective inhibitor 6, 7, 8, 9, 10, 11, 12, 13, 14, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, the 2, 8-deuterated dimethyl-2-(trifluoromethyl)-2H-benzopyran-3-carboxylic acid disclosed by the invention has the effects of remarkably relieving liver injury, reducing necrosis focus and inflammatory cell infiltration of liver cells and resisting cholestatic hepatic fibrosis; in addition, hepatocyte lipid accumulation and ballooning induced by high fat diet can be reduced, and the progress of lipid hepatitis is remarkably inhibited; it is found for the first time that the traditional Chinese medicine composition can significantly reduce the concentration of serum bilirubin and play a role in relieving hyperbilirubinemia caused by liver injury or liver insufficiency; the traditional Chinese medicine composition can be used for treating neonatal jaundice, congenital bile duct atresia, cholestatic cirrhosis, acute toxic hepatic failure, bilirubin increase caused by acute attack of chronic hepatitis, chronic hepatic failure or hepatic encephalopathy and the like; therefore, the method has obvious economic benefit and clinical application value.

The invention provides application of an immune response biomarker in prognosis evaluation of mesenchymal stromal cells in treatment of liver cirrhosis patients, and relates to the technical field of biomedicine, the immune response biomarker comprises MX1 positive monocytes or / and LGALS2 positive monocytes, and the MX1 positive monocytes are MX1 positive monocytes or / and LGALS2 positive monocytes. Screening to obtain a potential biomarker LGALS2 positive mononuclear cell and an MX1 positive mononuclear cell for predicting the MSC treatment dose-effect relationship; compared with a healthy control, the proportion of baseline MX1 positive monocytes of a liver cirrhosis patient is remarkably increased (Plt; 0.01), while the proportion of LGALS2 positive monocytes is significantly reduced (Plt; 0.05) of the substrate (1); the change trend of the biomarker under the same MSC dose and the regulation effect on other immune cell subgroups are identified through sequencing analysis, the dose-effect relationship of MSC-mediated immune regulation can be accurately reflected, and patients with low MSC treatment prognosis recurrence risk can be identified.

The invention relates to a patient decision support system and operating method based on self-care algorithms that evaluate patient activity for patients diagnosed with liver cirrhosis, which is intended to monitor and manage patients' health conditions, provides regular data tracking and personalised recommendations, tracks patients' daily and weekly activities, medication use, diet, and exercise routines, collects and evaluates the data, and presents user-specific recommendations, and which uses artificial intelligence and care algorithms to determine, on the basis of the patient's health data, which treatment and care pathways are the most appropriate.

The present invention relates to the use of exosomes comprising a superrepressor-I [kappa] B (srI [kappa] B) for the treatment of liver disease. The present invention provides a pharmaceutical composition for preventing or treating a liver disease, the pharmaceutical composition comprising an exosome containing a superrepressor-I [kappa] B (srI [kappa] B) as an active ingredient, the liver disease being hepatic fibrosis, cirrhosis, fatty liver, alcoholic liver disease, cholestasis, or a combination thereof.

The invention provides a hybridoma cell strain, a monoclonal antibody, a sensitization latex stock solution, and preparation methods and kits thereof. The method for preparing the sensitization latex stock solution by adopting the monoclonal antibody comprises the following steps: latex microspheres are added into the monoclonal antibody for coupling, the concentration of the monoclonal antibody is 6.2-7.4 mg / mL, and the sensitization latex stock solution is obtained. The kit comprises the monoclonal antibody. The hybridoma cell strain provided by the invention can secrete the CHI3L1 monoclonal antibody, and when the secreted CHI3L1 monoclonal antibody is used for auxiliary diagnosis of hepatic fibrosis and liver cirrhosis, the sensitivity and specificity are very good.